Want to join the conversation?
During 3Q15, $JNJ filed for Marketing Authorization in Europe for daratumumab, a treatment for patients with relapsed/refractory multiple myeloma, which received accelerated assessment from the CHMP. Daratumumab was granted Priority Review in the US. $JNJ submitted a SNDA to US FDA for IMBRUVICA for treatment of naive chronic lymphocytic leukemia.
$KMB down close to 4% after it misses on earnings and revenue. Forecasts are lower for the year.
It is official, with $T buying $TWX, it looks like distributors want to own the content production too. Expect some good competition between Netflix ($NFLX), AT&T, Comcast ($CMCSA) and others. However, will this be good for the consumers will not be decided soon.
$NFLX a monster move, going up. Expect making some money on Monday.